Harmone Receptor-positive, HER2-negative Early Breast Cancer Adjuvant Use of Abemaciclib nearly halves the Incidence of Distant Metastases

被引：0
|
作者：
Ruedesheim, Sabine M.
机构：
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2023年 / 46卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Comparison of Safety and Treatment Continuity of Palbociclib and Abemaciclib for Hormone Receptor-Positive, HER2-Negative Metastatic/Recurrent Breast Cancer
    Go, Makiko
    Kimura, Michio
    Yamada, Shiori
    Usami, Eiseki
    Noguchi, Yoshihiro
    Yoshimura, Tomoaki
    JOURNAL OF PHARMACY PRACTICE, 2024, 37 (06) : 1258 - 1266
  • [22] A metastasis biomarker (MetaSite Breast™ Score) is associated with distant recurrence in hormone receptor-positive, HER2-negative early-stage breast cancer
    Joseph A. Sparano
    Robert Gray
    Maja H. Oktay
    David Entenberg
    Thomas Rohan
    Xiaonan Xue
    Michael Donovan
    Michael Peterson
    Anthony Shuber
    Douglas A. Hamilton
    Timothy D’Alfonso
    Lori J. Goldstein
    Frank Gertler
    Nancy E. Davidson
    John Condeelis
    Joan Jones
    npj Breast Cancer, 3
  • [23] A metastasis biomarker (MetaSite Breast™ Score) is associated with distant recurrence in hormone receptor-positive, HER2-negative early-stage breast cancer
    Sparano, Joseph A.
    Gray, Robert
    Oktay, Maja H.
    Entenberg, David
    Rohan, Thomas
    Xue, Xiaonan
    Donovan, Michael
    Peterson, Michael
    Shuber, Anthony
    Hamilton, Douglas A.
    D'Alfonso, Timothy
    Goldstein, Lori J.
    Gertler, Frank
    Davidson, Nancy E.
    Condeelis, John
    Jones, Joan
    NPJ BREAST CANCER, 2017, 3
  • [24] Hormone receptor-positive, HER2-negative metastatic breast cancer: redrawing the lines
    Matutino, A.
    Joy, A. A.
    Brezden-Masley, C.
    Chia, S.
    Verma, S.
    CURRENT ONCOLOGY, 2018, 25 : S131 - S141
  • [25] Palbociclib for the Treatment of Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
    Morikawa, Aki
    Henry, N. Lynn
    CLINICAL CANCER RESEARCH, 2015, 21 (16) : 3591 - 3596
  • [26] Sacituzumab govitecan for hormone receptor-positive HER2-negative advanced breast cancer
    Garrigos, Laia
    Camacho, Daniela
    Perez-Garcia, Jose Manuel
    Llombart-Cussac, Antonio
    Cortes, Javier
    Antonarelli, Gabriele
    EXPERT REVIEW OF ANTICANCER THERAPY, 2024, 24 (10) : 949 - 958
  • [27] Ribociclib for the treatment of advanced hormone receptor-positive, HER2-negative breast cancer
    Lopez-Tarruella, Sara
    Jerez, Yolanda
    Marquez-Rodas, Ivan
    Echavarria, Isabel
    Martin, Miguel
    FUTURE ONCOLOGY, 2017, 13 (24) : 2137 - 2149
  • [28] Should patients with hormone receptor-positive, HER2-negative breast cancer and one or two positive sentinel nodes undergo axillary dissection to determine candidacy for adjuvant abemaciclib?
    Williams, Austin D.
    Ruth, Karen
    Shaikh, Saba S.
    Vasigh, Mahtab
    Pronovost, Mary T.
    Aggon, Allison A.
    Porpiglia, Andrea S.
    Bleicher, Richard J.
    CANCER, 2024, 130 (07) : 1052 - 1060
  • [29] Erratum to: Post-relapse survival in patients with the early and late distant recurrence in estrogen receptor-positive HER2-negative breast cancer
    Akiko Ogiya
    Kieko Yamazaki
    Rie Horii
    Tadahiko Shien
    Yoshiya Horimoto
    Norikazu Masuda
    Touko Inao
    Mitsuchika Hosoda
    Naoko Ishida
    Tomofumi Osako
    Masato Takahashi
    Yumi Endo
    Yuichiro Miyoshi
    Hiroyuki Yasojima
    Nobumoto Tomioka
    Hiroko Yamashita
    Breast Cancer, 2017, 24 : 642 - 642
  • [30] Risk of Abemaciclib-induced Liver Injury in Hormone Receptor-positive, HER2-negative Metastatic Breast Cancer: A Retrospective Analysis
    Taniguchi, Azusa
    Kittaka, Nobutohi
    Kanaoka, Haruka
    Nakajima, Satomi
    Oyama, Yuri
    Seto, Yukiko
    Soma, Ai
    Kusama, Hiroki
    Watanabe, Noriyuki
    Matsui, Saki
    Nishio, Minako
    Fujisawa, Fumie
    Nakayama, Takahiro
    ANTICANCER RESEARCH, 2022, 42 (12) : 6027 - 6035
12345